Inhibition of LPA-LPAR1 and VEGF-VEGFR2 Signaling in IPF Treatment

作者：Ya-Li Luo, Yan Li, Wen Zhou, Siyu Wang, Yongqi Liu · 发表于：Drug Design Development and Therapy · 年份：2023 · DOI：10.2147/dddt.s415453 · 被引用次数：12 · 研究领域：Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis、Pulmonary Hypertension Research and Treatments、Eosinophilic Disorders and Syndromes

Due to the complex mechanism and limited treatments available for pulmonary fibrosis, the development of targeted drugs or inhibitors based on their molecular mechanisms remains an important strategy for prevention and treatment. In this paper, the downstream signaling pathways mediated by VEGFR and LPAR1 in pulmonary cells and the role of these pathways in pulmonary fibrosis, as well as the current status of drug research on the targets of LPAR1 and VEGFR2, are described. The mechanism by which these two pathways regulate vascular leakage and collagen deposition leading to the development of pulmonary fibrosis are analyzed, and the mutual promotion of the two pathways is discussed. Here we propose the development of drugs that simultaneously target LPAR1 and VEGFR2, and discuss the important considerations in targeting and safety.